4-Methylquinazoline Derivatives as Selective PI3Kδ Inhibitors for Acute Lung Injury

A novel series of 4-methylquinazoline derivatives were designed and synthesized as potent PI3Kδ inhibitors. Lead compound 48 exhibited single-digit nanomolar potency and exceptional selectivity over other PI3K isoforms. Deyu Wu published this preclinical candidate data on figshare in May 2026.

Use Cases

• Structure-activity relationship analysis based on the series of synthesized quinazoline derivatives
• Selectivity profiling of kinase inhibitors based on the described selectivity over other PI3K isoforms
• Preclinical efficacy evaluation based on the murine models of LPS-induced acute lung injury
• Pharmacokinetic property analysis based on the favorable PK properties mentioned for compound 48

Strengths

• Lead compound 48 demonstrated single-digit nanomolar potency against PI3Kδ
• Compound 48 showed exceptional selectivity over other class I PI3K isoforms
• Data includes results from murine models of LPS-induced ALI and septic lung injury

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

figshare

Collection Method

Structure-based drug design, chemical synthesis, and in vitro/in vivo biological evaluation.

Freshness

Last updated 2026-05-24 13:08:36